SITE005-0262

SITE005 (FRA) › SITE005-0262

SITE005-0262

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2026-07-12

enrolled

AEs

2

Serious

1

Dropout signal

–

Adverse events

2

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-02 (study day 21); relationship: RELATED; serious criteria: hospitalization

severe serious assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 7); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.